title: The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.
abstract: The native HIV-1 Tat protein was chosen as a vaccine candidate based on its key role in the virus life cycle and on the correlation of Tat-specific immune responses with the asymptomatic stage and lower disease progression rates, but also due to its sequence conservation amongst the various HIV clades as well as the adjuvant effects on dendritic cells. Safety, immunogenicity and efficacy data in monkeys support the development of this vaccine concept.
authors.affiliation: National AIDS Center, Istituto Superiore di Sanità, Rome, Italy. barbara.ensoli@iss.it
authors.forename: Barbara
authors.initials: B
authors.lastname: Ensoli
authors.forename: Valeria
authors.initials: V
authors.lastname: Fiorelli
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Ensoli
authors.forename: Adriano
authors.initials: A
authors.lastname: Lazzarin
authors.forename: Raffaele
authors.initials: R
authors.lastname: Visintini
authors.forename: Pasquale
authors.initials: P
authors.lastname: Narciso
authors.forename: Aldo
authors.initials: A
authors.lastname: Di Carlo
authors.forename: Paolo
authors.initials: P
authors.lastname: Monini
authors.forename: Mauro
authors.initials: M
authors.lastname: Magnani
authors.forename: Enrico
authors.initials: E
authors.lastname: Garaci
mesh_terms: D016915:AIDS Vaccines / Q000009:adverse effects* / Q000276:immunology; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D015483:HIV Antibodies / Q000096:biosynthesis; D015658:HIV Infections / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D011994:Recombinant Proteins / Q000009:adverse effects / Q000276:immunology; D019562:Viral Load; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000009:adverse effects* / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D011994:Recombinant Proteins; D054322:tat Gene Products, Human Immunodeficiency Virus